Colon Cancer Diagnosis and Therapy: Volume 1
暫譯: 結腸癌診斷與治療：第一卷

Nagaraju, Ganji Purnachandra, Shukla, Dhananjay, Vishvakarma, Naveen Kumar

Colon Cancer Diagnosis and Therapy: Volume 1
  • 出版商: Springer
  • 出版日期: 2021-06-11
  • 售價: $6,780
  • 貴賓價: 9.5 折 $6,441
  • 語言: 英文
  • 頁數: 369
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 3030633683
  • ISBN-13: 9783030633684

    • 海外代購書籍(需單獨結帳)

相關主題

商品描述

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.
This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

商品描述(中文翻譯)

結直腸癌（CRC）是全球健康的一大挑戰，為全球癌症相關死亡的第三大原因。儘管治療策略有所進展，CRC患者的五年存活率隨時間推移仍然保持不變，因為患者通常在晚期轉移階段被診斷出來。藥物抗藥性是另一個導致預後不良的常見原因。研究人員目前正在開發先進的治療策略，如免疫療法、靶向療法和結合納米技術的藥物傳遞。此外，新的生物標記的識別將促進早期診斷。

本書是關於結直腸診斷和治療近期發展的三卷本中的第一卷。每一卷都可以單獨閱讀，也可以一起閱讀。每一卷專注於不同的新型治療進展、生物標記，並識別治療目標。由該領域的國際領先專家撰寫，內容還涉及飲食習慣和生活方式在減少胃腸疾病和結直腸癌發病率中的作用。各章節討論了結直腸癌患者目前和未來的診斷及治療選擇，重點關注免疫治療、納米醫學、生物標記和飲食因素，以有效管理結腸癌。

作者簡介

Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and PhD, both in Biotechnology from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his D.Sc. from Berhampur University in Berhampur, Odisha, India. Nagaraju's research focuses on translational research in gastrointestinal malignancies. He has published over 100 research papers in highly respected international journals and has presented more than 50 abstracts at various national and international conferences. He is the author and editor of several books. Dr. Nagaraju is an editorial board member of several internationally recognized academic journals, and is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is a member of the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), the Science Advisory Board, The RNA Society and the American Association of Cancer Research (AACR).
Dr. Dhananjay Shukla is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Shukla received his PhD in Biotechnology from Defense Institute of Physiology and Allied Science, New Delhi, India. Dr. Shukla has expertise in cancer physiology and has published more than 25 research papers in various highly reputed international journal. He has presented and been invited to lecture at a number national and international conferences.
Dr. Naveen Kumar Vishvakarma is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Vishvakarma received his PhD in Biotechnology from Banaras Hindu University, Varanasi, India. He has published more than 20 research papers in highly reputed journals on various aspects of cancer biology. He has written a number of book chapters for international publishers and presented abstract at national and international conferences.

作者簡介(中文翻譯)

Dr. Nagaraju GP 是美國埃默里大學醫學院血液學與醫學腫瘤學系的教職員。Nagaraju 博士在印度安得拉邦的提魯帕提的斯里維克拉斯瓦拉大學獲得生物技術碩士和博士學位。Nagaraju 博士在印度奧里薩邦的貝漢普爾大學獲得科學博士學位。Nagaraju 的研究專注於腸胃道惡性腫瘤的轉化研究。他在多個受尊敬的國際期刊上發表了超過 100 篇研究論文，並在各種國內外會議上發表了超過 50 篇摘要。他是幾本書的作者和編輯。Nagaraju 博士是幾本國際認可的學術期刊的編輯委員會成員，並且是 Winship 癌症研究所發現與發展治療研究計畫的副會員。他是美國印度裔科學家協會 (ASIOA)、綜合與比較生物學學會 (SICB)、科學諮詢委員會、RNA 協會和美國癌症研究協會 (AACR) 的成員。
Dr. Dhananjay Shukla 是印度古魯·哈西達斯大學（中央大學）生物技術系的助理教授。Shukla 博士在印度新德里的國防生理學與相關科學研究所獲得生物技術博士學位。Shukla 博士在癌症生理學方面具有專業知識，並在多個享有盛譽的國際期刊上發表了超過 25 篇研究論文。他在多個國內外會議上發表演講並受邀講授。
Dr. Naveen Kumar Vishvakarma 是印度古魯·哈西達斯大學（中央大學）生物技術系的助理教授。Vishvakarma 博士在印度瓦拉納西的班納拉斯印度大學獲得生物技術博士學位。他在多個享有盛譽的期刊上發表了超過 20 篇有關癌症生物學各個方面的研究論文。他為國際出版社撰寫了多個書章，並在國內外會議上發表了摘要。

類似商品